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Abstract
Dysregulation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B/mammalian target of rapamycin signaling is common 
in both indolent and aggressive forms of malignant lymphoma, for which several targeted therapies have been developed. 
Copanlisib is a highly selective and potent intravenous pan-class I PI3K inhibitor that has demonstrated durable objective 
responses and a manageable safety profile in heavily pre-treated patients with indolent lymphomas. As a result, copanlisib 
monotherapy received accelerated approval from the US Food and Drug Administration for the treatment of adults with 
relapsed follicular lymphoma who have received at least two systemic therapies, and breakthrough designation for patients 
with pre-treated relapsed or refractory marginal zone lymphoma. Hyperglycemia and hypertension are among the most 
frequently reported adverse events with copanlisib monotherapy, and are infusion-related, transient, and manageable with 
standard therapies. Mild diarrhea is also a common adverse event with copanlisib monotherapy; there is no evidence of 
worsening severity of diarrhea, or serious gastrointestinal toxicities such as colitis or severe liver enzyme elevations, which 
have been reported with orally administered PI3K inhibitors. The intravenous route of administration and intermittent dosing 
schedule of copanlisib may support a favorable tolerability profile over continually administered oral alternatives. Ongoing 
studies of copanlisib in combination with rituximab and standard-of-care chemotherapy in patients with relapsed indolent 
lymphoma have the potential to support the use of copanlisib in the second-line setting, providing a much-needed additional 
therapeutic option in this underserved patient population.
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1 Introduction
Phosphatidylinositol 3-kinase (PI3K)/protein kinase B 
(AKT)/mammalian target of rapamycin (mTOR) signaling 
is a vital intracellular pathway, regulating fundamental cell 
functions including cell growth, survival, and proliferation 
[1, 2]. PI3K/AKT/mTOR signaling also plays a pivotal role 
in several metabolic processes, including mediating insulin 
and glucose metabolism [3]. PI3Ks consist of a family of 
plasma membrane-associated lipid kinases, and are catego-
rized into three classes [4]. Class I PI3Ks are heterodimers 
containing a catalytic subunit, p110, encoded by PIK3CA, 
PIK3CB, PIK3CD, or PIK3CG, which give rise to four iso-
forms (p110α, p110β, p110γ, and p110δ), respectively, and 
a regulatory subunit, p85 [4]. Class I PI3Ks can generate 
phosphoinositide 3,4,5 trisphosphate, which is thought to be 
essential for PI3K-mediated oncogenicity, while class II and 
III PI3Ks lack this function [4]. Dysregulation and aberrant 
activation of PI3K can lead to a disturbance of healthy cell 
growth and survival, with subsequent neoplastic transforma-
tion [4, 5]. PI3K has been implicated in the tumorigenesis 
of many human cancers, which makes it an attractive thera-
peutic target for cancer [5].
PI3K/AKT/mTOR signaling is frequently deregulated 
in malignant lymphoma, leading to uncontrolled prolifera-
tion of B cells [6]. Malignant lymphomas are heterogene-
ous and typically fall into two prognostic groups: indolent 
and aggressive [7, 8]. Follicular lymphoma (FL) and diffuse 
large B cell lymphoma (DLBCL) represent the most com-
mon forms of indolent and aggressive lymphoma, respec-
tively [9]. For patients with FL, approximately 20% will 
experience early relapse and disease progression within 
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Key Points 
Copanlisib monotherapy has demonstrated durable and 
rapid objective responses in patients with heavily pre-
treated indolent lymphoma, with a manageable safety 
profile, and is approved for the treatment of patients with 
relapsed follicular lymphoma.
The intravenous route of administration and intermittent 
dosing schedule of copanlisib may support a favorable 
tolerability profile over continuously administered oral 
alternatives.
Ongoing studies are evaluating the safety and efficacy of 
copanlisib in combination with rituximab and standard-
of-care chemotherapy in patients with relapsed indolent 
lymphoma and may support the use of copanlisib in the 
second-line setting as part of a combination regimen if 
the results are positive.
that were associated with the combination [23]. Similarly, 
a phase I study of duvelisib in combination with rituximab 
alone or rituximab and bendamustine in patients with CLL 
and relapsed/refractory NHL demonstrated toxicities that 
were consistent with those reported for the respective single 
agents [24]. Continued development of PI3K inhibitors has 
therefore been necessary in order to provide safe and effec-
tive treatment options for this underserved population. Tar-
geted therapies under investigation include the oral PI3K-δ 
inhibitor umbralisib, currently being evaluated in FL patients 
with POD24 (SWOG1608 study, NCT03269669). Umbral-
isib is being explored for the treatment of patients with pre-
viously treated marginal zone lymphoma (MZL) and FL 
in the UNITY-NHL phase IIb study [25]. The oral PI3K-δ 
inhibitor parsaclisib was also recently investigated in a phase 
II study of patients with relapsed or refractory DLBCL 
(CITADEL-202, NCT02998476); the study was terminated 
due to futility, but evaluation in combination with standard 
therapies is ongoing [26]. Other classes of agent in early 
clinical development in the third-line setting for patients 
with relapsed/refractory B cell lymphoma include CD19-
directed chimeric antigen receptor T cell immunotherapy 
[27–29], bi-specific anti-CD20/CD3 monoclonal antibod-
ies (mosunetuzumab [30] and epcoritamab [31]), and the 
EZH2 inhibitor tazemetostat, which has recently obtained 
accelerated FDA approval for the treatment of patients with 
relapsed or refractory FL and mutated EZH2 who have been 
treated with at least two therapies [32].
Copanlisib is a highly selective and potent intravenous 
pan-class I PI3K inhibitor, with predominant activity against 
the PI3K-α and PI3K-δ isoforms [33]. Following the obser-
vation of promising anti-tumor activity in preclinical studies 
[33], the first-in-human phase I study of copanlisib estab-
lished that copanlisib could be safely administered intra-
venously in a continuous 1-h infusion, on an intermittent 
schedule of days 1, 8, and 15 of a 28-day cycle, with the 
maximum tolerated dose (MTD) identified as 0.8 mg/kg 
[34]. This phase I study, together with the subsequent pivotal 
phase II CHRONOS-1 study, demonstrated that copanlisib 
is safe and well tolerated, with the most common AEs being 
hyperglycemia and hypertension, both of which are known 
to be transient and manageable, and did not lead to signifi-
cant treatment discontinuation during the studies [34–36]. 
Based on the phase II CHRONOS-1 study (NCT01660451; 
part B), copanlisib 60 mg was granted accelerated approval 
by the FDA for the treatment of adults with relapsed FL who 
have received at least two systemic therapies, and does not 
have a black box warning regarding toxicities [37].
The intravenous route of administration and the intermit-
tent schedule of dosing for copanlisib make it unique among 
PI3K inhibitors, both approved and in development. Here, 
we review the properties of copanlisib, summarizing the 
known efficacy and safety profile of copanlisib to date in 
24 months (POD24) following standard first-line chemo-
therapy, which is a predictor of lessened overall survival 
(OS) [9–13]. Evidence for activation of the PI3K/AKT/
mTOR pathway has been demonstrated in samples from FL 
and DLBCL patients, suggesting that activation of the path-
way may be involved in the pathogenesis of non-Hodgkin 
lymphoma (NHL) [14–16].
Therapies, both oral and intravenous, have been developed 
to target different components of the PI3K/AKT pathway 
in malignant lymphoma; one selective PI3K-α and PI3K-δ 
inhibitor, copanlisib (Aliqopa; Bayer AG, Berlin, Germany), 
administered intermittently and intravenously once weekly 
for 3 weeks on and 1 week off, and two selective PI3K-δ 
inhibitors, idelalisib and duvelisib, administered orally on 
a continuous twice-daily schedule, have been approved for 
treatment of relapsed and refractory FL [17–19], with other 
novel therapies currently under investigation. However, high 
rates of autoimmune and infectious toxicities have raised 
concerns over the safety of orally administered PI3K inhibi-
tors, resulting in US Food and Drug Administration (FDA) 
black box warnings for hepatotoxicity, diarrhea or colitis, 
pneumonitis, and intestinal perforation with idelalisib [18], 
and infections, diarrhea or colitis, cutaneous reactions, and 
pneumonitis with duvelisib [17, 20, 21]. Oral PI3K inhibi-
tors have also demonstrated some tolerability issues in com-
bination with earlier lines of therapy, and a number of com-
bination studies were discontinued due to safety concerns 
[22]. In a phase I, open-label study of idelalisib in com-
bination with bendamustine or rituximab in patients with 
chronic lymphocytic leukemia (CLL), 75% developed sig-
nificant serious adverse events (AEs), including infections, 
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studies including patients with indolent and aggressive types 
of lymphoma. We will consider the future of copanlisib and 
summarize ongoing clinical studies.
2  Activity of Copanlisib in Preclinical 
and Clinical Studies
Copanlisib has demonstrated potent anti-proliferative activ-
ity in multiple cell lines, with half maximal inhibitory con-
centration values of less than 10 nmol/L [33]. Consistent 
with the reported in vitro activity, intravenously adminis-
tered copanlisib demonstrated anti-tumor activity in cell-
derived and patient-derived xenograft models [38], including 
in rat xenograft models derived from human colon tumors 
carrying PIK3CA and KRAS mutations, and mouse xenograft 
models established from patient-derived, erlotinib-resistant, 
non-small cell lung carcinoma and luminal breast cancer 
[33]. Interestingly, prolonged levels of copanlisib were seen 
in tumors compared with plasma after intravenous dosing, 
and a once-weekly schedule had similar anti-tumor effects 
as an every-other-day schedule. Together, the preclinical 
efficacy findings provided rationale to evaluate copanlisib 
in human studies.
Class I PI3Ks have been shown to play a key role in mam-
malian insulin signaling, linking the activation of the insu-
lin receptor to glucose metabolism, with the PI3K-α and 
PI3K-β isoforms primarily involved in this process [39, 40]. 
Insulin-receptor signaling is driven by PI3K-α and PI3K-β 
phosphorylation of AKT, with both isoforms demonstrating 
functional redundancy [39]. Dysregulation of PI3K signal-
ing downstream of the insulin receptor has been shown to be 
a contributor to the pathophysiology of type 2 diabetes [41]. 
In vivo, reduced insulin sensitivity, impaired glucose toler-
ance, and increased gluconeogenesis have been observed in 
mice with a hepatic knockout of p110α [42]. Accordingly, 
hyperglycemia has been a common and expected on-target 
effect of PI3K inhibition in phase I clinical studies [43–46], 
including in the first-in-human study of copanlisib, where 
hyperglycemia events were transient, asymptomatic, and 
manageable [34].
A phase I pharmacodynamic study has provided clear 
evidence of PI3K pathway on-target activity of copanlisib 
in patients with malignant lymphoma and advanced solid 
tumors, supporting a mode of action [47] (see Fig. 1). In that 
study, levels of pS6, a target downstream of phosphorylated 
AKT, exhibited dose-dependent reductions in lymphoma 
and solid tumor biopsies following treatment with copan-
lisib [47].
Immune cell types other than B cells have various func-
tions in different tumor environments and can influence 
disease prognosis; for instance, high levels of  CD4+ T lym-
phocytes and low levels of  CD8+ T lymphocytes (compris-
ing subsets of tumor-infiltrating lymphocytes) have been 
associated with a poor prognosis in patients with glioma 
[48]. In addition, there was a significantly higher  CD4+ and 
 CD8+ T lymphocyte count at the tumor–host interface than 
within the intratumoral stroma in a report of triple-negative 
breast cancer [49], and a high proportion of  CD8+ cyto-
toxic T lymphocytes correlated with improved prognostic 
outcome in a report of non-small cell lung cancer [50]. 
In a small number of patients with malignant lymphoma 
and advanced solid tumors, a preliminary finding of dose-
dependent reduction in  CD4+ cells was observed in tumor 
Fig. 1  Mode of action of 
copanlisib. FOXO Forkhead 
Box subfamily O transcrip-
tion factors, GSK3 glycogen 
synthase kinase-3, IC50 half 
maximal inhibitory concentra-
tion, IR insulin receptor, mTOR 
mammalian target of rapamycin, 
pAKT phosphorylated AKT, PD 
pharmacodynamic, PI3K phos-




















PD markers in blood




298 J. Munoz et al.
biopsies following copanlisib treatment compared with base-
line, with little effect observed in the proportion of  CD8+ 
cells [47]. Although these results were not conclusive based 
on the small sample size, these data could suggest a role for 
copanlisib in immunosuppression through inhibition of the 
PI3K signaling pathway and warrant further investigation.
3  Activity of Copanlisib Monotherapy 
in Indolent Lymphoma
3.1  Phase I Studies
The first-in-human phase I study enrolled and treated six 
patients with FL in an NHL expansion cohort (nine patients 
in total), at the MTD level of 0.8 mg/kg intravenous copan-
lisib on days 1, 8, and 15 of a 28-day cycle [51]. Promis-
ing efficacy outcomes were observed in patients with FL 
[34], summarized in Table 1. The separate phase I pharma-
cokinetic/pharmacodynamic study of copanlisib included 
one patient with grade 3a FL, who received intravenous 
copanlisib 0.8 mg/kg on the same intermittent schedule [47], 
and achieved a partial response (PR) as a best response (see 
Table 1).
3.2  Phase II Studies
Following the positive tolerability findings and early signs of 
efficacy in all FL patients treated in the first-in-human phase 
I study, an open-label phase II study (NCT01660451; part 
A) was initiated to evaluate copanlisib efficacy and safety 
in heavily pre-treated patients with relapsed or refractory 
malignant lymphoma [52]. This study enrolled and treated 
33 patients with indolent lymphoma, including 16 patients 
with FL, 13 patients with CLL, three patients with MZL, 
and one patient with small lymphocytic lymphoma. Patients 
received intravenous copanlisib at the phase I MTD level, 
0.8 mg/kg, on the intermittent schedule (days 1, 8, and 15 
of a 28-day cycle). Overall, 32 patients with indolent lym-
phoma had measurable lesions at baseline and were evalu-
able for response, with three patients achieving a complete 
response (CR) [including one with an unconfirmed CR] 
Table 1  Summary of efficacy outcomes from clinical studies of copanlisib in patients with indolent lymphoma
CLL chronic lymphocytic leukemia, CR complete response, DCR disease control rate, FL follicular lymphoma, LPL/WM lymphoplasma-
cytic lymphoma/Waldenstrӧm’s macroglobulinemia, MZL marginal zone lymphoma, ORR objective response rate, POD24 progression within 
24 months, PR partial response, SD stable disease, SLL small lymphocytic lymphoma
a One patient was excluded because they did not have any measurable lesion as per Cheson criteria at baseline; therefore, 15 patients were evalu-
able for response
b One patient achieved an unconfirmed CR
c One patient with unconfirmed SD and four with SD or PR recorded > 35 days from the last treatment were excluded
d Includes one patient with unconfirmed early SD (SD was assessed earlier than 7 weeks after start of treatment, with no radiologic assessment of 
SD, PR, or CR at later cycles)
Study Histology Number of 
patients
ORR,  % (CR; PR) DCR,  % (SD)
Phase I
NCT00962611 [34] FL 6 100 (2; 4) 100 (0)
NCT02155582 [47] FL 1 100 (0; 1) 100 (0)
Phase II
NCT01660451; part A [52] FL 16a 40.0  (3b; 3) 93.3 (8)
CLL 13 38.5 (0; 5) 84.6 (6)
MZL 3 66.7 (0; 2) 100 (1)
SLL 1 100 (0; 1) 100 (0)
NCT01660451; part B [35] FL 104 58.7 (15; 46) 87.5c (35)
MZL 23 69.6 (2; 14) 87.0 (4)
SLL 8 75.0 (0; 6) 87.5 (1)
LPL/WM 6 16.7 (0; 1) 66.7 (3)
NCT01660451; part B long-term follow-up [36] FL 104 58.7 (21; 40) 87.5  (35d)
MZL 23 78.3 (3; 15) 87.0 (2)
SLL 8 75.0 (0; 6) 87.5 (1)
LPL/WM 6 16.7 (0; 1) 66.7 (3)
NCT01660451; part B FL POD24 subset (Leppä et al.; 
submitted)
FL (POD24) 68 60.3 (15; 26) 88.2 (21)
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and 11 with a PR as best response. The objective response 
rate (ORR) was 43.8%, and the disease control rate (DCR) 
was 90.6% (15 patients with stable disease [SD]); Table 1 
presents ORRs and DCRs per histology. Median time to 
response was 1.7 months (range 0–3.6) and median pro-
gression-free survival (PFS) was 9.7 months (range 0–28.7), 
with a median duration of response (DoR) of 12.8 months 
(range 0–27.1). Median OS was 21.6 months (range 0–31.5); 
at 12 months, OS was 69% [52].
Copanlisib demonstrated a promising efficacy profile 
in patients with indolent lymphoma in the phase I and 
phase II studies. Based on these results, the large, phase 
II CHRONOS-1 study (NCT01660451; part B) was initi-
ated to evaluate copanlisib in patients with relapsed or 
refractory indolent B cell lymphoma [35]. A total of 142 
patients with indolent lymphoma were enrolled and treated 
in CHRONOS-1, including 104 patients with FL, 23 
patients with MZL, eight patients with small lymphocytic 
lymphoma, and six patients with lymphoplasmacytic lym-
phoma/Waldenstrӧm’s macroglobulinemia (one patient was 
initially assessed by the investigator as having FL but was 
later confirmed to have DLBCL by the investigator and by 
central pathology review; this patient was included in the 
full analysis set). Patients in CHRONOS-1 received copan-
lisib 60 mg as a 1-h infusion on the intermittent schedule 
of days 1, 8, and 15 of a 28-day cycle; this was equiva-
lent to the 0.8 mg/kg MTD intermittent dosing schedule as 
defined in the phase I study [34]. The overall ORR for the 
study was 59.2%, exceeding the prespecified threshold of 
40% (95% confidence interval 51–67; P < 0.001); ORRs and 
DCRs by histological subgroup are summarized in Table 1. 
Patients with FL had an ORR of 59% (including 15 CRs), 
and the patients with MZL had an ORR of 70% (including 
two CRs). Overall, median DoR was 22.6 months (range 
0–22.6), with responses being rapid and durable (a median 
time to response of 53 days). Median PFS was 11.2 months 
(range 0.2–24.0), and median OS had not been reached by 
the data cut-off point. For patients with FL, median DoR 
was 12.2 months (range 0–22.6). Of 125 evaluable patients 
with indolent lymphoma in this study, 74 (59.2%) exhibited 
at least a 50% reduction in target lesion size following treat-
ment with copanlisib [35]. Based on the primary data from 
CHRONOS-1, copanlisib received accelerated approval 
from the FDA for the treatment of patients with relapsed 
FL who had received two or more therapies, adding to the 
available treatment options in the third-line setting for this 
advanced and heavily pre-treated population.
A 2-year follow-up of the 142 patients with indolent 
lymphoma from the phase II CHRONOS-1 study showed 
that the responses to treatment with copanlisib seen at 
the time of the primary analysis were sustained and dura-
ble, even enhanced, over prolonged treatment [36]. At the 
time of the primary analysis, 17 and 67 patients achieved 
a CR and PR, respectively (ORR of 59.2%) [35]. At the 
2-year follow-up, 24 and 62 patients achieved a CR and 
PR, respectively, giving an ORR of 60.6%; the increased 
proportion of patients with a CR is indicative of enhanced 
response to copanlisib over time [36]. In this 2-year follow-
up analysis, six patients who initially had a PR achieved 
a CR, and one patient who had SD achieved a PR at the 
later cut-off. Of the seven additional CRs observed at the 
2-year follow-up, six were observed in patients with FL and 
one was observed in a patient with MZL. The proportion 
of patients with SD remained unchanged, as did the overall 
DCR (85.9%). Table 1 summarizes ORRs and DCRs per 
histology; the ORR in patients with FL was unchanged at 
the time of follow-up, whereas the ORR for patients with 
MZL increased from 70% to 78% (Panayiotidis et al.; sub-
mitted). Analyses at the 2-year follow-up showed short 
times to reach objective responses: the overall median time 
to response was 1.8 months (range 1.3–17.3), with a median 
of 4.7 months to CR (range 1.5–20.9). Overall, median DoR 
was 14.1 months (range 0.03–42.5), but was 26 months 
(range 1.9–34.5 months) in patients who had achieved a CR. 
Median PFS was 12.5 months (range 0.03–44.2 months), 
with a PFS rate at 2  years of 34%. Median OS was 
42.6 months (range 0.2–49.9), with an OS rate at 2 years of 
69%. Of 126 patients evaluable for lesion size, 116 patients 
(92.1%) demonstrated a reduction in target lesion size, with 
79 patients (62.7%) demonstrating a reduction in size of at 
least 50% following treatment with copanlisib [36].
An exploratory analysis of the results from the 2-year 
follow-up of CHRONOS-1 focused on the effects of copan-
lisib treatment in patients with FL with POD24, a subset of 
patients deemed to be of highest risk [53, 54] and represent-
ing a population with the greatest unmet clinical need. Of 
the 68 patients treated in CHRONOS-1 with FL and with 
POD24, 15 and 26 patients achieved a CR and PR, respec-
tively, giving an ORR of 60.3% (Leppä et al.; submitted), 
which was similar to the ORR for the overall FL population 
(58.7%). Patients with FL with POD24 had a median DoR of 
10.9 months (range 0–42.5), a median PFS of 11.3 months 
(range 0–44.2), and a median OS of 38.3 months (range 
0.7–49.8); efficacy outcomes were broadly comparable 
with those of FL patients without POD24 (median DoR of 
12.2 months [range 0–34.2], median PFS of 10.8 months 
[range 0–35.8], and median OS of 31.0  months [range 
3.0–43.0]). These results reflect robust and durable responses 
in patients with FL regardless of disease progression status 
and including those with potentially high-risk disease, and 
the data indicate that copanlisib could be a viable therapeutic 
option for the most difficult to treat patients (Leppä et al.; 
submitted).
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4  Activity of Copanlisib Monotherapy 
in Aggressive Lymphoma
The first-in-human phase I study of copanlisib enrolled and 
treated three patients with DLBCL [34]. Patients received 
copanlisib 0.8 mg/kg as a single intravenous infusion over 
1 h on days 1, 8, and 15 of a 28-day cycle. Of these patients, 
one patient achieved a PR and two patients had progressive 
disease as best response (see Table 2).
In the open-label, phase II study of copanlisib in patients 
with relapsed and refractory malignant lymphoma, 51 
patients with aggressive lymphoma were enrolled and treated 
with copanlisib 0.8 mg/kg on the intermittent dosing sched-
ule (days 1, 8, and 15 of a 28-day cycle). Of these patients, 
17 had peripheral T cell lymphoma (including three patients 
with anaplastic large-cell lymphoma and four patients with 
angioimmunoblastic T cell lymphoma), 15 had DLBCL, 11 
had mantle cell lymphoma, six had transformed indolent FL, 
and one patient each had mediastinal large B cell lymphoma 
and grade 3b FL. Of the 48 patients with aggressive lym-
phoma available for response, CRs and PRs were observed 
in four (two confirmed CRs and two unconfirmed CRs) and 
nine patients, respectively, resulting in an ORR of 27.1%. 
Eleven patients had SD, giving a DCR of 50.0%. Table 2 
summarizes ORRs and DCRs by histology. Median time 
to response was 51 days (range 0–117) for the aggressive 
lymphoma cohort, median PFS was 70 days (range 0–897), 
and PFS at 12 months was 13%. Median DoR was 166 days 
(range 0–786) and median OS was 183 days (range 0–1017), 
with a 12-month OS rate of 42%.
More recently, following on from the ORR of 6.7% in the 
DLBCL subgroup of patients treated with copanlisib in the 
phase II study in indolent and aggressive lymphoma [52], 
an open-label, phase II study was performed to evaluate 
the efficacy and safety of copanlisib specifically in patients 
with relapsed or refractory DLBCL [55]. In this study, 
two major molecular subtypes of DLBCL were evaluated, 
activated B cell-like (ABC) DLBCL and germinal center 
B cell-like (GCB) DLBCL, both of which have proven to 
differ in their clinical outcomes and responsiveness to treat-
ment [56, 57]. Patients received copanlisib 60 mg as a 1-h 
intravenous infusion on days 1, 8, and 15 of a 28-day cycle; 
overall, 19 and 30 patients with ABC DLBCL and GCB 
DLBCL, respectively, were evaluable for response. The 
ORR for all patients was 19.4%. For patients with ABC 
DLBCL, four patients and two patients achieved a CR and 
PR, respectively, giving an ORR of 31.6% (see Table 2). 
Median DoR was 4.3 months (range 1.3–20.2), median 
PFS was 2.4 months (range 0.5–15.3), and median OS was 
6.9 months (range 0.5–27.6). Of the 15 patients with ABC 
DLBCL with calculable percentage changes from baseline in 
target lesions, seven patients (46.7%) demonstrated a reduc-
tion in target lesion size of greater than 50%. For patients 
with GCB DLBCL, one patient and three patients achieved a 
CR and PR, respectively, resulting in an ORR of 13.3% (see 
Table 2). Median DoR was 6.0 months (range 2.1–20.2), 
median PFS was 1.7 months (range 0.03–21.9), and median 
Table 2  Summary of efficacy outcomes from clinical studies of copanlisib in patients with aggressive lymphoma
ABC activated B cell-like, CR complete response, DCR disease control rate, DLBCL diffuse large B cell lymphoma, FL follicular lymphoma, 
GCB germinal center B cell-like, MCL mantle cell lymphoma, ORR objective response rate, PR partial response, PTCL peripheral T cell lym-
phoma, SD stable disease
a Includes three patients with anaplastic large-cell lymphoma and four patients with angioimmunoblastic T cell lymphoma
b 14 patients with PTCL were evaluable for response
c Includes two unconfirmed CRs
d Grade 3b
Study Histology Number of 
patients
ORR,  % (CR; PR) DCR,  % (SD)
Phase I
NCT00962611 [34] DLBCL 3 33.3 (0; 1) 33.3 (0)
Phase II
NCT01660451; part A [52] PTCL 17a,b 21.4 (2; 1) 57.1 (5)
DLBCL 15 6.7 (0; 1) 46.7 (6)
MCL 11 63.6  (2c; 5) 63.6 (0)
Transformed indolent FL 6 33.3 (0; 2) 33.3 (0)
Mediastinal large B cell lymphoma 1 0 0
FLd 1 0 0
NCT02391116 [55] ABC DLBCL 19 31.6 (4; 2) 52.6 (4)
GCB DLBCL 30 13.3 (1; 3) 40.0 (8)
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OS was 9.4 months (range 0.2–29.4). Of the 24 patients 
with GCB DLBCL with calculable percentage changes from 
baseline in target lesions, four patients (16.7%) had a reduc-
tion in target lesion size of greater than 50%. Although the 
difference in ORR between ABC DLBCL and GCB DLBCL 
was not statistically significant (P = 0.1413) [55], these data 
appear to support preclinical studies suggesting that patients 
with ABC DLBCL may respond preferentially to PI3K inhi-
bition, despite their worse prognosis, compared with patients 
with GCB DLBCL [58, 59].
5  Safety
Safety data from the first-in-human phase I study of copan-
lisib in patients with indolent and aggressive lymphoma 
demonstrated good tolerability with copanlisib [34]. Of 
the nine patients with malignant lymphoma included in 
the study (six with FL and three with DLBCL), the most 
common drug-related AEs (all grade) were hyperglycemia 
(88.9%), nausea (77.8%), hypertension, diarrhea, fatigue, 
and oral mucositis (33.3% each) (see Table 3). Grade 3 and 
grade 4 drug-related AEs were observed in five patients 
(55.6%) and one patient (11.1%), respectively, with no drug-
related grade 5 events reported. Hyperglycemia and hyper-
tension were the most frequent drug-related grade 3 AEs 
in this small cohort (33% each), followed by drug-related 
rash/desquamation (11%). Dose delays, interruptions, and 
reductions arising from drug-related AEs were observed in 
14 patients (25%), and four patients discontinued as a result 
of AEs. One drug-related AE leading to discontinuation was 
recorded: a dose-limiting toxicity (DLT) of left ventricular 
systolic dysfunction.
Safety data from the 84 patients with indolent and 
aggressive lymphoma from the phase II, part A study of 
copanlisib [52] reflected a safety profile consistent with 
the phase I study [34]. The most commonly reported treat-
ment-emergent AEs (TEAEs) were hyperglycemia (59.5%), 
hypertension (54.8%), fatigue (48.8%), diarrhea (40.5%), 
and decreased neutrophil count (34.5%) (see Table 3); in 
most cases, grade 3 was the worst grade of TEAE. There 
were ten deaths, including four considered possibly related 
to copanlisib. Serious TEAEs of grade 3, 4, and 5 were 
reported in 26 patients (31.0%), four patients (4.8%), and 
ten patients (11.9%), respectively, with serious drug-related 
AEs recorded in 32.1% of patients. Permanent treatment 
discontinuation due to TEAEs was reported in 25% of 
patients. Dose interruptions or delays and dose reductions 
due to TEAEs were experienced by 50 patients (59.5%) and 
11 patients (13.1%), respectively, with a median duration of 
dose interruption or delay of 1 week (range 0.1–1.7).
In the 142 patients with relapsed or refractory indolent 
lymphoma in the phase II, part B CHRONOS-1 study [35], 
the safety profile of copanlisib remained consistent with the 
previously discussed lymphoma cohorts [34, 52]; the most 
common TEAEs were hyperglycemia (50.0%), diarrhea 
(33.8%), fatigue, hypertension (30.3% each), and decreased 
neutrophil count (29.6%) (see Table 3). The most common 
grade 3 or 4 TEAEs were grade 3 hyperglycemia (34%), 
grade 3 hypertension (24%), grade 4 neutropenia (16%), 
and grade 3 lung infection (13%). There were six deaths 
(4%), including three that were considered drug-related: 
lung infection, respiratory failure, and a cerebral thrombo-
embolic event in one patient each. Treatment discontinuation 
due to TEAEs was reported in 36 patients (25.4%), and these 
TEAEs were considered drug-related in 23 patients (16.2%). 
Safety data from the 2-year follow-up of these patients 
remained consistent with the primary analysis, with no new 
or unexpected TEAEs reported over the longer treatment 
duration [36] (see Table 3).
In the phase II study of patients with DLBCL [55], treat-
ment with copanlisib demonstrated a safety profile that 
was recognizable and consistent with the earlier studies 
in patients with malignant lymphoma. In the 67 patients 
enrolled and treated, the most common TEAEs were hyper-
tension (40.3%), diarrhea (37.3%), hyperglycemia (32.8%), 
nausea (31.3%), and fatigue (28.4%) (see Table 3). These 
events were also among the most frequent events that were 
considered drug-related in this population. There were 14 
deaths (20.9%), although none of these was deemed to be 
drug-related. Dose reductions and interruptions/delays 
due to TEAEs were reported in nine patients (13.4%) and 
34 patients (50.7%), respectively, with TEAEs leading to 
permanent discontinuation in 17 patients (25.4%). Serious 
TEAEs were observed in 44 patients (65.7%).
Hyperglycemia (based on the Common Terminology Cri-
teria for Adverse Events version 4 or lower) and hyperten-
sion constitute two of the most frequently reported TEAEs 
across all of the studies of copanlisib in patients with malig-
nant lymphoma; hyperglycemia is a recognized class effect 
of PI3K inhibition [43–46]. Most cases of hyperglycemia 
and hypertension were of grade ≤ 3 and were manageable. 
In the first-in-human phase I study of copanlisib, hypergly-
cemia was not a DLT for patients treated at the MTD level 
of 0.8 mg/kg and was considered transient, infusion-related, 
and manageable, with blood glucose values returning to 
baseline levels within 24 h, and to normal levels before 
the next infusion [34]. Similarly, dose-dependent transient 
increases in plasma glucose were observed following copan-
lisib treatment in the pharmacodynamic study of copanlisib 
[60]. In the first-in-human study, hypertension was experi-
enced by approximately one-third of patients, but was also 
observed to be transient, with increases in blood pressure 
returning to baseline levels within 24 h following first copan-
lisib infusion [34]. With hypertension not generally reported 
with other PI3K inhibitors, it has been proposed that the high 
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frequency of monitoring and the intravenous route of deliv-
ery with copanlisib may possibly account for some reported 
differences in TEAE profiles for PI3K inhibitors [46, 61], 
including the intravenous pan-PI3K/mTOR inhibitor pic-
tilisib [62]. It has been suggested that the hypertension fol-
lowing copanlisib-mediated PI3K inhibition may be caused 
by dysregulation of endothelial-derived vasoconstrictors and 
vasodilators [63–66], or increased insulin levels [66, 67]. In 
the phase II, part A study, all hyperglycemia and hyperten-
sion events followed the same, predicted profile of being 
transient and infusion-related, with no patient discontinuing 
treatment as a result [52]. Post-infusion hyperglycemia and 
hypertension events were managed with insulin and anti-
hypertensive treatments.
Similarly, hyperglycemia and hypertension were tran-
sient and were not a significant cause of treatment dis-
continuation in the CHRONOS-1 phase II, part B study 
[35]. In CHRONOS-1, infusion-related hyperglycemia 
was largely self-limiting, asymptomatic, and did not lead 
to significant discontinuation from treatment. Management 
Table 3  Summary of most common TEAEs in copanlisib clinical studies in patients with indolent and aggressive lymphoma
Top five AEs with the highest incidence per study are in bold
AE adverse event, TEAE treatment-emergent adverse event
a Drug-related TEAEs are presented for this study
b Dose reduction to 45 mg
c Dose reduction to 30 mg
d Maculopapular
Study Phase I Phase II







B long-term follow-up 
[36]
NCT02391116 [55]
Number of patients 9 84 142 142 67





AEs leading to dose 
interruptions/modifi-
cations, n (%)
14 (25.0) 50 (59.5)/11 (13.1) 105 (73.9)/37 (26.1)b; 
8 (5.6)c
116 (81.7)/40 (28.2) 34 (50.7)/9 (13.4)
Grade 5 AEs, n (%) 0 10 (11.9) 6 (4.2) 6 (4.2) 14 (20.9)
AEs in ≥ 15% of 
patients (any grade), 
n (%)
Hyperglycemia 8 (88.9) 50 (59.5) 71 (50.0) 71 (50.0) 22 (32.8)
Nausea 7 (77.8) 28 (33.3) 33 (23.2) 33 (23.2) 21 (31.3)
Hypertension 3 (33.3) 46 (54.8) 43 (30.3) 42 (29.6) 27 (40.3)
Diarrhea 3 (33.3) 34 (40.5) 48 (33.8) 50 (35.2) 25 (37.3)
Decreased neutrophil 
count/neutropenia
– 29 (34.5) 42 (29.6) 41 (28.9) 7 (10.4)
Fatigue 3 (33.3) 41 (48.8) 43 (30.3) 37 (26.1) 19 (28.4)
Anemia – 24 (28.6) 22 (15.5) 25 (17.6) –
Rash/desquamation 2 (22.2) – 18 (12.7)d – 9 (13.4)
Oral mucositis 3 (33.3) 19 (22.6) 28 (19.7) – –
Lung infection – 17 (20.2) 30 (21.1) – –




– 15 (17.9) 29 (20.4) 20 (14.1) –
Headache – 15 (17.9) – – 9 (13.4)
Urinary tract infection – 14 (16.7) – – –
Dyspnea – 14 (16.7) – – 7 (10.4)
Constipation – 13 (15.5) 17 (12.0) 18 (12.7) 11 (16.4)
Cough – 10 (11.9) 23 (16.2) 27 (19.0) 12 (17.9)
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of hyperglycemia with adequate hydration via oral fluids 
was satisfactory for most patients, although insulin or oral 
glucose-lowering agents (including metformin, a glucose 
cotransporter 2 inhibitor, and a dipeptidyl peptidase-4 inhib-
itor) were used in patients with diabetes, those with persis-
tent hyperglycemia despite adequate hydration, or those who 
were symptomatic. Safety data from the 2-year follow-up of 
the patients from the CHRONOS-1 phase II, part B study 
echoed the results from primary analysis, with hypergly-
cemic and hypertensive events remaining infusion-related, 
transitory, and manageable over the prolonged treatment 
duration, with no evidence of new or worsening events over 
time, and a trend toward a reduction in both TEAEs with 
longer treatment duration compared with earlier time points 
[36]. However, as reported in that study, this effect could 
be attributed to the longer-term and better management of 
these conditions, or possibly the development of tolerance. 
All reported incidences of hyperglycemic and hypertensive 
TEAEs in the phase II study of patients with DLBCL were 
grade ≤ 3, transitory, and considered to be manageable in 
this population [55].
A key differentiator between the safety profiles of intra-
venous copanlisib and continuously administered oral PI3K 
inhibitors, including idelalisib and duvelisib, is the lower 
rate of severe gastrointestinal toxicities seen with copan-
lisib, such as colitis and severe liver enzyme elevations [36, 
68, 69]. Idelalisib has also been shown to be associated 
with risk of inflammatory reactions, including hepatitis and 
pneumonitis, in addition to reactivation of cytomegalovirus 
and severe Pneumocystis jirovecii-related pulmonary infec-
tions [70], leading to five black box warnings [18]. Duvel-
isib carries four black box warnings, including fatal and/or 
serious infections, diarrhea or colitis, cutaneous reactions, 
and pneumonitis [17, 71]. Diarrhea has been frequently 
reported as a TEAE from studies with copanlisib treatment, 
although most events were mild in severity (grade < 4) [34, 
35, 52] and manageable with symptomatic treatment such 
as loperamide [52]. This was reflected in the 2-year long-
term follow-up of the CHRONOS-1 phase II study with 
low overall rates of diarrhea and no evidence of worsening 
severity of diarrhea over time [36]. In addition, low rates 
of colitis and elevated liver enzymes (alanine transami-
nase and aspartate aminotransferase) have been observed 
with copanlisib. The clinical study results with copanlisib 
to date suggest that the intravenous route of administration 
and intermittent dosing schedule may together contribute 
toward an improved tolerability profile when compared with 
continuously dosed oral agents. However, although intermit-
tent intravenous administration of copanlisib may provide 
beneficial outcomes and long-term tolerability, it will be 
important to consider the impact of the intravenous route 
of administration on convenience and logistics for therapy 
in some patients, particularly considering the current global 
coronavirus disease 2019 (COVID-19) pandemic. Logis-
tic challenges with in-person clinic visits may require the 
development of alternative administration schedules in the 
future, and in the shorter term, methods of administering 
intravenous therapies in a way that patients can be safely 
treated and monitored while minimizing the risk of exposure 
to further illness are required.
6  Copanlisib in Ongoing and Combination 
Studies
Based on the clinical data to date, intravenous copanlisib has 
shown positive efficacy results and favorable tolerability in 
patients with indolent lymphoma [35, 36] in relation to the 
landscape of continuously administered oral PI3K inhibitors, 
warranting further clinical study as part of a combination 
regimen. Further study of copanlisib in this setting is also 
particularly relevant for populations with the highest unmet 
need, such as those with aggressive lymphomas, and it is 
desirable to improve upon the modest single-agent ORR 
for copanlisib in patients with DLBCL [55]; combination 
regimens may be better equipped to overcome limitations 
and inherent resistance to inhibition that may be observed 
with a monotherapy approach. With demonstrated on-target 
PI3K inhibitory activity, copanlisib is currently being evalu-
ated as part of several different combination regimens as to 
whether the targeted activity of copanlisib can improve upon 
standard-of-care chemotherapy (see Table 4). Additional 
monotherapy trials are also ongoing in different patient 
populations, including those with solid tumors.
Two large, randomized, phase III studies are ongoing to 
explore the combinability of copanlisib with standard ther-
apy for patients with indolent B cell lymphoma who have 
progressed on one or more lines of therapy. CHRONOS-3 
(NCT02367040) is a phase III, randomized, double-blind, 
placebo-controlled study of copanlisib in combination with 
rituximab in patients with relapsed or refractory indolent 
lymphoma. Primary efficacy and safety data are expected to 
be reported in early 2021. CHRONOS-4 (NCT02626455) 
is a phase III, randomized, double-blind, placebo-con-
trolled study that aims to evaluate the efficacy and safety 
of copanlisib in combination with rituximab and stand-
ard chemotherapy (R-B [rituximab plus bendamustine] or 
R-CHOP [rituximab plus cyclophosphamide, doxorubicin, 
vincristine, and prednisone]) in patients with relapsed B cell 
indolent lymphoma; preliminary data from the safety run-in 
phase to evaluate the feasibility of this combination have 
recently been reported [72]. The safety run-in phase was 
based on an open-label, two-dose level, 3 + 3 design. R-B 
and R-CHOP were each tested at two copanlisib doses (45 
and 60 mg), with a minimum of three and maximum of six 
patients evaluable for DLT at each dose level. Copanlisib 
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was administered on days 1, 8, and 15 of a 28-day cycle with 
R-B, or on days 1 and 8 of a 21-day cycle with R-CHOP, for 
up to six cycles. Copanlisib monotherapy was administered 
from cycle 7 for up to 12 months. There were no DLTs at 
either copanlisib dose level in either treatment arm, and the 
recommended phase III dose of copanlisib in combination 
with standard immunotherapy was defined as 60 mg for both 
immunochemotherapy combinations. All patients in both 
treatment groups experienced TEAEs, the most common of 
which were decreased neutrophil count, nausea, decreased 
platelet count, and hyperglycemia, consistent with the 
known safety profile of copanlisib monotherapy [34, 35]; 
there were no cases of colitis. These preliminary data sug-
gest that copanlisib in combination with standard immu-
nochemotherapy has an acceptable safety and tolerability 
profile. The phase III portion of CHRONOS-4 is currently 
ongoing to assess the efficacy of copanlisib versus placebo in 
combination with immunochemotherapy, with an estimated 
primary completion date of 2022. Copanlisib is currently 
approved for use in patients who have been treated with two 
or more therapies; however, these studies have the potential 
to validate copanlisib as an effective treatment option for 
patients following initial relapse.
7  Conclusions and Future Perspectives
To date, phase I and phase II studies of copanlisib in patients 
with malignant lymphoma have demonstrated durable and 
sustained anti-tumor activity, with a distinct yet manage-
able safety profile. Durable and rapid objective responses 
have been observed in patients with heavily pre-treated 
indolent lymphoma, particularly FL and MZL. Based on 
this, copanlisib received breakthrough designation for pre-
treated MZL in 2019. Responses to copanlisib have shown 
to be sustained, even enhanced, in patients with indolent 
lymphoma, with prolonged treatment [36]. Copanlisib 
has demonstrated robust activity in patients with FL with 
POD24, a subset who are deemed to have the highest unmet 
need. The results to date support the feasibility of copan-
lisib treatment and support its use in heavily pre-treated 
patients with indolent lymphoma. Patients with aggressive 
lymphoma are difficult to treat, with treatment options typi-
cally being very limited; there is an urgent need for novel 
therapeutic strategies. Copanlisib has demonstrated anti-
lymphoma activity in a phase II study, with favorable effi-
cacy in patients with DLBCL (an overall ORR of 19.4% and 
an overall DCR of 40.3%) [55]. It is anticipated that ongoing 
Table 4  Summary of ongoing copanlisib studies
CLL chronic lymphocytic leukemia, DLBCL diffuse large B cell lymphoma, FL follicular lymphoma, MCL mantle cell lymphoma, MZL mar-
ginal zone lymphoma, NHL non-Hodgkin lymphoma, NK natural killer, SLL small lymphocytic lymphoma
Treatment(s) Indication Phase Study name Status Country NCT identifier
Copanlisib NHL I Active, not recruiting China NCT03498430
Copanlisib Advanced solid tumor I/II Recruiting US NCT03735628
Copanlisib NHL III CHRONOS-2 Active, not recruiting Multinational NCT02369016
Copanlisib NHL Ib/II Active, not recruiting Japan NCT02342665
Copanlisib Mixed malignant tumor I/II Recruiting US NCT03458728
Copanlisib NHL II CHRONOS-1 Active, not recruiting Multinational NCT01660451
Copanlisib and ibrutinib MCL I/II Active, not recruiting US NCT03877055
Copanlisib and rituximab MZL II Recruiting Austria, Germany NCT03474744
Copanlisib and gemcitabine Mature T cell and NK cell 
neoplasm
I/II Active, not recruiting Republic of Korea NCT03052933
Copanlisib and nivolumab Colorectal cancer I/II Recruiting US NCT03711058
Copanlisib and rucaparib Prostate cancer I/II Recruiting US NCT04253262
Copanlisib, bendamustine, 
and rituximab
Lymphoid leukemia, NHL, 
CLL, SLL
II Recruiting US NCT04155840
Copanlisib and rituximab NHL III CHRONOS-3 Active, not recruiting Multinational NCT02367040
Copanlisib and standard 
immunochemotherapy
NHL III CHRONOS-4 Active, not recruiting Multinational NCT02626455
Copanlisib, gemcitabine, 
carboplatin, dexametha-
sone, rituximab, and 
pegfilgrastim
DLBCL, FL Ib Recruiting US NCT04156828
Copanlisib and rogaratinib Advanced or metastatic solid 
tumor
I Active, not recruiting Multinational NCT03517956
Copanlisib, gemcitabine, and 
cisplatin
Cholangiocarcinoma II Active, not recruiting US NCT02631590
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studies of copanlisib in combination with standard-of-care 
chemotherapy will provide additional therapeutic strategies 
in these underserved populations.
Key considerations for administering copanlisib therapy 
include awareness of the known safety profile, the route 
of administration, and preferences regarding infusion at 
the treating center. The most frequent TEAEs of transient 
hyperglycemia and hypertension are largely self-limiting 
and have been demonstrated to resolve following copan-
lisib infusion; recommendations for management include 
glucose-lowering medications and short-acting anti-hyper-
tensive medications, respectively. For patients with blood 
pressure above 150/90 mmHg while on copanlisib treat-
ment, it is recommended that anti-hypertensive medication 
continues until there are two consecutive readings of less 
than 150/90 mmHg [71]. Treatment-emergent diarrhea is 
also common with copanlisib therapy, although usually not 
severe, and recommendations are available on managing 
diarrhea during copanlisib therapy, initially focusing on con-
servative management [71]. The intravenous route of admin-
istration and intermittent schedule may support the favorable 
tolerability profile of copanlisib, but oral therapies may be 
preferred in some treating centers over others. However, oral 
therapies pose unique challenges to treatment adherence for 
patients with lymphoma, in addition to potentially contrib-
uting to higher out-of-pocket patient costs compared with 
intravenous therapies, which may present a barrier to access 
[73, 74]. It should be noted, however, that the logistics and 
convenience of intravenous administration are likely to be 
affected by the current global COVID-19 pandemic.
In the current landscape of FDA-approved therapies in 
advanced malignant lymphoma, copanlisib is the only intra-
venously administered PI3K inhibitor agent available. With 
the ongoing development of further oral PI3K inhibitors 
in this setting, results from clinical studies of intravenous 
copanlisib confirming its feasibility in combination with 
immunochemotherapy regimens may offer urgently needed 
additional therapeutic options for pre-treated patients with 
malignant lymphoma in the second-line setting, as well as 
continuing to support the use of copanlisib in patients with 
relapsed FL and, pending FDA approval, MZL, in the third-
line setting.
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